We are live on ! Find out more
DCM

DAFNA Capital Management Portfolio holdings

AUM $524M
1-Year Est. Return 164.42%
This Fund
S&P 500
This Quarter Est. Return
-4.59%
1 Year Est. Return
+164.42%
3 Year Est. Return
+313.04%
5 Year Est. Return
+302.83%
10 Year Est. Return
+4,361.99%
AUM
$99.1M
AUM Growth
-$6.37M
Cap. Flow
+$1.03M
Cap. Flow %
1.04%
Top 10 Hldgs %
58.86%
Holding
65
New
16
Increased
6
Reduced
7
Closed
6

Top Buys

Rank Stock Value
1
ASPX
AUSPEX PHARMACEUTICALS INC COM STK (DE)
ASPX
+$3.23M
2
OCRX
Ocera Therapeutics, Inc.
OCRX
+$2.97M
3
AERI
Aerie Pharmaceuticals
AERI
+$2.87M
4
CLVS
Clovis Oncology, Inc.
CLVS
+$1.54M
5
NBIX icon
Neurocrine Biosciences
NBIX
+$989K

Top Sells

Rank Stock Value
1
AMPE
Ampio Pharmaceuticals Inc.
AMPE
+$7.02M
2
VXRT
Vaxart
VXRT
+$2.08M
3
ARCT icon
Arcturus Therapeutics
ARCT
+$1.47M
4
KERX
Keryx Biopharmaceuticals Inc
KERX
+$1.42M
5
GLMD icon
Galmed Pharmaceuticals
GLMD
+$678K

Sector Composition

Rank Sector Weight
1 Healthcare 74.58%
2 Miscellaneous 24.32%
3 Financials 1.1%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PCYC
1
DELISTED
PHARMACYCLICS INC
PCYC
$13M 13.14%
110,928
-4,700
-4% -$536K
WINT
2
DELISTED
Windtree Therapeutics Inc
WINT
$10.5M 10.58%
407,053
– –
ATRC icon
3
AtriCure
ATRC
$2.47B
$8.82M 8.89%
598,883
+27,896
+5% +$444K
NXTM
4
DELISTED
NxStage Medical Inc.
NXTM
$5.04M 5.09%
384,154
– –
PODD icon
5
Insulet
PODD
$10.1B
$4.03M 4.07%
109,418
– –
ASPX
6
DELISTED
AUSPEX PHARMACEUTICALS INC COM STK (DE)
ASPX
$3.9M 3.94%
+152,002
New +$3.23M
NVDQ
7
DELISTED
Novadaq Technologies Inc.
NVDQ
$3.34M 3.37%
263,541
– –
OCRX
8
DELISTED
Ocera Therapeutics, Inc.
OCRX
$3.31M 3.34%
675,650
+515,028
+321% +$2.97M
DSCI
9
DELISTED
Derma Sciences, Inc. Common Stock (DE)
DSCI
$3.21M 3.23%
384,794
– –
STXS icon
10
Stereotaxis
STXS
$145M
$3.19M 3.22%
1,718,719
-8,106
-0.5% -$19.4K
PLX icon
11
Protalix BioTherapeutics
PLX
$205M
$3.12M 3.14%
128,844
+11,000
+9% +$317K
AERI
12
DELISTED
Aerie Pharmaceuticals
AERI
$3.01M 3.03%
+145,342
New +$2.87M
BSTC
13
DELISTED
BioSpecifics Technologies Corp.
BSTC
$2.12M 2.14%
60,054
-10,034
-14% -$295K
MTEM
14
DELISTED
Molecular Templates, Inc.
MTEM
$2.01M 2.02%
3,369
+987
+41% +$683K
CLVS
15
DELISTED
Clovis Oncology, Inc.
CLVS
$1.67M 1.69%
+36,900
New +$1.54M
CRDC
16
DELISTED
CARDICA INC COM NEW (DE)
CRDC
$1.59M 1.6%
148,600
– –
BEAT
17
DELISTED
BioTelemetry, Inc.
BEAT
$1.58M 1.59%
235,645
– –
XNPT
18
DELISTED
XENOPORT, INC.
XNPT
$1.29M 1.3%
240,190
– –
UPI
19
DELISTED
UROPLASTY INC-NEW
UPI
$1.22M 1.23%
486,062
+44,203
+10% +$115K
SPNC
20
DELISTED
Spectranetics Corp
SPNC
$1.12M 1.13%
42,162
– –
RIOT icon
21
Riot Platforms
RIOT
$7.13B
$1.09M 1.1%
82,250
– –
NBIX icon
22
Neurocrine Biosciences
NBIX
$15.7B
$1.04M 1.04%
+66,141
New +$989K
GLMD icon
23
Galmed Pharmaceuticals
GLMD
$4.34M
$1.01M 1.01%
81
-62
-43% -$678K
JNJ icon
24
Johnson & Johnson
JNJ
$646B
$1M 1.01%
9,400
– –
ECI
25
DELISTED
ENCISION INC
ECI
$983K 0.99%
1,062,500
– –
1
2 3

Similar funds

4WM
49 Wealth Management Austin, Texas $524M AUM 16.59% 1-Year Est. Return
BB
Berkshire Bank Pittsfield, Massachusetts $524M AUM 21.97% 1-Year Est. Return
A
Alongside Austin, Texas $525M AUM
HW
Hedeker Wealth Lincolnshire, Illinois $524M AUM 36.83% 1-Year Est. Return
DAM
Decagon Asset Management London, United Kingdom $525M AUM 50.51% 1-Year Est. Return
SDWIA
Schwarz Dygos Wheeler Investment Advisors Minneapolis, Minnesota $524M AUM 25.1% 1-Year Est. Return
SCA
Stieven Capital Advisors St. Louis, Missouri $524M AUM 29.72% 1-Year Est. Return
BHPW
Beverly Hills Private Wealth Beverly Hills, California $525M AUM 24.1% 1-Year Est. Return

DAFNA Capital Management's Q3 2014 Portfolio in Review

As of Q3 2014, DAFNA Capital Management held 65 positions worth $99.1M, down 6% from $106M the previous quarter. Its ten largest holdings account for 59% of the portfolio.

DAFNA Capital Management's Q3 2014 filing shows 16 new, 6 increased, 7 reduced and 6 closed positions. Its largest new stake was AUSPEX PHARMACEUTICALS INC COM STK (DE): 152,002 shares worth $3.9M. The largest sale was Ampio Pharmaceuticals Inc., an estimated $7.02M.

By sector, the portfolio is most concentrated in Healthcare at 75% of assets, down from 82% a quarter earlier, followed by Miscellaneous and Financials.

  • DAFNA Capital Management's largest Q3 2014 buy was AUSPEX PHARMACEUTICALS INC COM STK (DE): 152,002 shares worth $3.9M.
  • DAFNA Capital Management added most to Ocera Therapeutics, Inc. in Q3 2014, an estimated $2.97M increase.
  • DAFNA Capital Management's biggest Q3 2014 reduction was Ampio Pharmaceuticals Inc., cutting an estimated $7.02M.
  • DAFNA Capital Management fully exited Vaxart in Q3 2014, selling an estimated $2.08M.
  • DAFNA Capital Management's ten largest holdings make up 59% of its $99.1M portfolio in Q3 2014.
  • DAFNA Capital Management opened 16 new positions and closed 6 in Q3 2014.
  • DAFNA Capital Management's portfolio value fell 6% quarter-over-quarter to $99.1M.

Based on DAFNA Capital Management's 13F filing for Q3 2014, filed 14 Nov 2014.